XML 55 R39.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Quarterly Financial Information (Unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract] |
Schedule of quarterly financial information (unaudited) | The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2016 and 2015 (unaudited):
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2016 |  | September 30, 2016 |  | June 30, 2016 |  | March 31, 2016
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenue: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 476,586 |  |  | $ | 2,327,316 |  |  | $ | 1,889,988 |  |  | $ | 1,796,857 |
Revenue under collaborative research and development arrangements with affiliated entity | 189,278 |  |  | 574,596 |  |  | 499,720 |  |  | 137,000 |
Grants and miscellaneous revenue | 7,735,428 |  |  | 9,410,648 |  |  | 3,814,083 |  |  | 6,176,298 |
Grants and miscellaneous revenue from affiliated entity | 112,660 |  |  | 227,903 |  |  | — |  |  | — |
Total revenues | 8,513,952 |  |  | 12,540,463 |  |  | 6,203,791 |  |  | 8,110,155 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 23,911,731 |  |  | 26,980,343 |  |  | 19,630,801 |  |  | 18,189,160 |
General and administrative | 6,965,517 |  |  | 5,755,603 |  |  | 5,799,530 |  |  | 5,371,613 |
Gain on sale of assets | — |  |  | — |  |  | (1,000,000 | ) |  | — |
Total operating expenses | 30,877,248 |  |  | 32,735,946 |  |  | 24,430,331 |  |  | 23,560,773 |
Loss from operations | (22,363,296 | ) |  | (20,195,483 | ) |  | (18,226,540 | ) |  | (15,450,618 | )
Interest and other income, net | 191,460 |  |  | 391,596 |  |  | 341,131 |  |  | 333,070 |
Change in fair value of common stock warrants | 644,888 |  |  | 2,690 |  |  | (113,775 | ) |  | (406,249 | )
Gain (Loss) from investment in affiliated entity | (4,706,522 | ) |  | (958,141 | ) |  | (705,527 | ) |  | 7,480,977 |
Net loss attributable to Inovio Pharmaceuticals, Inc. | $ | (26,233,470 | ) |  | $ | (20,759,338 | ) |  | $ | (18,704,711 | ) |  | $ | (8,042,820 | )
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders |  |  |  |  |  |  |
Basic | $ | (0.35 | ) |  | $ | (0.28 | ) |  | $ | (0.26 | ) |  | $ | (0.11 | )
Diluted | $ | (0.36 | ) |  | $ | (0.28 | ) |  | $ | (0.26 | ) |  | $ | (0.11 | )
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2015 |  | September 30, 2015 |  | June 30, 2015 |  | March 31, 2015
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenue: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 1,820,643 |  |  | $ | 16,475,083 |  |  | $ | 4,335,236 |  |  | $ | 4,245,571 |
Revenue under collaborative research and development arrangements with affiliated entity | 375,000 |  |  | 125,000 |  |  | 166,667 |  |  | 112,500 |
Grants and miscellaneous revenue | 3,739,919 |  |  | 7,583,151 |  |  | 784,775 |  |  | 808,566 |
Total revenues | 5,935,562 |  |  | 24,183,234 |  |  | 5,286,678 |  |  | 5,166,637 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 15,601,891 |  |  | 16,075,201 |  |  | 16,688,511 |  |  | 9,426,320 |
General and administrative | 4,860,086 |  |  | 4,377,616 |  |  | 4,718,260 |  |  | 4,107,928 |
Gain on sale of assets | — |  |  | — |  |  | (1,000,000 | ) |  | — |
Total operating expenses | 20,461,977 |  |  | 20,452,817 |  |  | 20,406,771 |  |  | 13,534,248 |
Income (Loss) from operations | (14,526,415 | ) |  | 3,730,417 |  |  | (15,120,093 | ) |  | (8,367,611 | )
Interest and other income, net | (194,519 | ) |  | 214,982 |  |  | 146,332 |  |  | 138,276 |
Change in fair value of common stock warrants | (290,316 | ) |  | 518,877 |  |  | (49,773 | ) |  | (1,227 | )
Gain (Loss) from investment in affiliated entity | (3,249,315 | ) |  | (659,054 | ) |  | 8,861,145 |  |  | (2,352,309 | )
Net income (loss) before income tax benefit | (18,260,565 | ) |  | 3,805,222 |  |  | (6,162,389 | ) |  | (10,582,871 | )
Income tax benefit | 308,520 |  |  | 1,789,246 |  |  | — |  |  | — |
Net income (loss) | (17,952,045 | ) |  | 5,594,468 |  |  | (6,162,389 | ) |  | (10,582,871 | )
Net (income) loss attributable to non-controlling interest | — |  |  | — |  |  | (85,861 | ) |  | 1,092 |
Net income (loss) attributable to Inovio Pharmaceuticals, Inc. | $ | (17,952,045 | ) |  | $ | 5,594,468 |  |  | $ | (6,248,250 | ) |  | $ | (10,581,779 | )
Net income (loss) per common share attributable to Inovio Pharmaceuticals, Inc. stockholders |  |  |  |  |  |  |
Basic | $ | (0.25 | ) |  | $ | 0.08 |  |  | $ | (0.09 | ) |  | $ | (0.17 | )
Diluted | $ | (0.25 | ) |  | $ | 0.07 |  |  | $ | (0.09 | ) |  | $ | (0.18 | )

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=68076893&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration